Keyword: Alzheon

Alzheimer’s drug developer Alzheon has pulled plans for a public listing on the Nasdaq for the second time in nine months.

After an aborted attempt earlier this year, Alzheon is having another go at an IPO to help fund new trials of its Alzheimer’s candidate tramiprosate.

Alzheon is still trying to build a case for a pivotal trial of its Alzheimer’s candidate and says new data support its plans.

Alzheon had planned to bankroll the phase 3 trial of its once-failed Alzheimer's drug with the IPO funds.

The IPO will equip Alzheon to take its reworking of a once-failed beta amyloid drug into a pivotal trial in a subset of Alzheimer’s patients.

The regulatory status sets the prodrug of tramiprosate up to speed through the FDA review process if it bucks the trend and hits the mark in phase 3.

As the world’s top researchers working in Alzheimer’s disease descend into Toronto for the AAIC this week, all will be coming with a continued show of hope--despite the slew of late-stage failures for the disease over the past decade.